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CHAPTER 41 
Increased Levels of Two Distinct 
Elastase-Like Hydrolases in Plasma 
During Septicemia 
L.P. N E L L E S and H.P. SCHNEBLI 
Ciba-Geigy, Pharma Research, Basel, Switzerland 
M. JOCHUM 
Abt. Klinische Chemie und Biochemie der Chirurg. Klinik Innenstadt, Universität München, 
München, Federal Republic of Germany 
Κ. Η. DUSWALD 
Chirurgische Klinik Innenstadt, Universität München, München, Federal Republic of Germany 
Introduction 
Many of the complications of septicemia 
are believed to be initiated by endotoxin, 
resulting i n activation of the complement 
system and, through Hageman factor, in 
massive activation of the k in in , coagula-
t ion, and fibrinolytic systems. Further-
more, endotoxin has been shown to stim-
ulate polymorphonuclear leukocytes to re-
lease large amounts of neutral proteinases, 
particularly elastase.1'2 Activation of the 
plasma proteolytic systems together w i t h 
the release of enzymes from the phagocytic 
cells may overwhelm the proteinase inhib-
itors, and therfore allow the proteinases to 
cause local tissue and organ damage. 2 In 
addition, granulocyte elastase may also 
contribute directly to "intravascular tur-
m o i l " through k i n i n formation, 3 activation 
and degradation of coagulation factor X I I I , 4 
as wel l as inactivation of antithrombin I I I , 5 
a key coagulation system regulator. 
The present experiments were under-
taken to measure and characterize elas-
tase(s) and other proteinases released into 
the plasma dur ing septicemia. Earlier re-
ports of immunreactive aj-antitrypsin elas-
tase complexes i n serum of septic patients 1 
and endotoxin-treated dogs 2 suggested that 
a 2 M ( a 2 - m a c r o g l o b i n ) - p r o t e i n a s e com-
plexes w o u l d also be present under these 
conditions. The methods used in the pre-
sent study are based on the fact that a 2 M -
bound proteinases retain hydrolytic activ-
ity toward small molecular weight syn-
thetic substrates, but are unable to attack 
large (protein substrates.) 8 
Materials and Methods 
Plasma samples were obtained from six 
patients w h o had undergone major ab-
dominal surgery and later developed sep-
ticemia. The samples were taken at irreg-
ular intervals for approximately 48 hours 
fol lowing signs of generalized infection. 
Control plasma was obtained from six 
healthy donors. 
Plasma proteinase levels were quantified 6 
by measuring the release of p-nitroaniline 
from the fol lowing chromogenic sub-
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strates: Succ-Ala 3-p-NA* (Bachem, Buben­
dorf, CH) , MeO-Succ-Ala 2 -Pro-Val-p-NAt 
(CIBA-GEIGY, Basle), substrates for elas-
taselike enzymes; Bz-Arg-p-NA;J (Sigma, 
St. Louis, M o . ) , a substrate for trypsinlike 
enzymes; and Succ-Phe-p-Na§ (Sigma), a 
substrate for chy mo trypsinlike enzymes. 
I n the assay, 0.2 m l of plasma was diluted 
w i t h 0.2 m l of 0.1 Μ Tris-Cl buffer, p H 7.5, 
containing 1 m M substrate (except for Succ-
A l a 3 - N A , which was 5 m M ) . The mixture 
was incubated at 37° C for 1-6 hours and 
the reaction was stopped by the addition 
of 1 m l of 7.5% trichloroacetic acid. The 
protein was removed by centrifugation, and 
the nitroaniline released was reacted to form 
a purple azo-dye by addition of 25 μΐ each 
of sodium nitrite (1.8%), ammonium sul-
famate (9%), and N-l-naphthyl-ethylene-
diamine d i - H C l (1.8%, Sigma). The ab-
sorbance of the colored product was 
measured at 550 n m . Alpha 2 -macroglobu-
l in was quantified according to a 
modification 6 of the method of Gantrot. 8 
Separation of elastaselike enzymes from 
plasma was accomplished by applying a 
2.75-ml sample to a column (2.6 x 94 cm) 
of Sephacryl S-300 superfine (Pharmacia, 
Uppsala), previously equilibrated w i t h 0.02 
Μ sodium citrate buffer, p H 6.5, w i t h 0.15 
Μ NaCl and 0.04% N a N 3 . The column was 
eluted w i t h the same buffer at a f low rate 
of 13.5 ml/hr. 
Results and D i s c u s s i o n 
Plasma samples taken at several times 
w i t h i n a 2-day period from six patients suf­
fering from severe septicemia were ana­
lyzed for their content of peptide hydro­







six normal volunteers. Plamsa f rom all six 
patients had markedly elevated levels of 
hydrolases cleaving the four substrates. The 
degree of elevation is illustrated Figure 1, 
where the hydrolase levels in pooled plasma 
from the normal individuals (N) and from 
the septic patients (S) are compared. 
I n order to examine more closely the 
elastase-like hydrolase activities i n septic 
plasma, a sample w i t h high activities was 
fractionated on a column of Sephacryl S-
300 superfine (Fig. 2, top). The hydrolase 
activity of the elastaselike enzymes showed 
two main peaks. The First peak (Peak I) 
had a molecular weight > 106 daltons and 
cleaved the Succ-Ala 3-p-NA substrate, but 
was nearly devoid of MeO-Succ-Ala 2-Pro-
Val-p-NA hydrolase activity. As shown in 
Table 1 , this enzyme was completely i n ­
activated by 1,10 phenanthroline, an i n ­
hibitor of metalloenzymes, but was insen­
sitive to phenyl-methyl-sulfonyl-fluoride 
(Pms-F), a small molecular weight inhibitor 
of serine proteinases, as well as to Eglin C 
and the Bowman-Birk soybean, both i n ­
hibitors of leukocyte elastase. In addit ion, 
it was sensitive to EDTA but unaffected by 
the sulfhydryl reagents, dithiothreitol β-
mercaptoe thanol. 
The second peak eluted together w i t h 
a 2 M ( M w ~ 8 x 105 daltons) and hydro-
lyzed both the MeO-Succ-Ala 2-Pro-Val-p-
N A and the Succ-Ala 3-p-NA substrates, the 
former being hydrolyzed about six times 
faster. This enzyme activity (Table 1) was 
insensitive to 1,10 phenanthroline, but it 
was sensitive toward Pms-F, as wel l as to­
ward Elgin C, which has previously been 
shown to inhibit leukocyte elastase com-
plexed w i t h a 2 M (M.J., unpublished ob­
servation). A significant degree of inhib i ­
tion is also observed w i t h the relatively small 
molecular weight Bowman-Birk soybean 
inhibitor. 
Based on the molecular weight, sub­
strate specificity, and inhibitor pattern, we 
conclude that the second peak of peptide 
hydrolase activity corresponds to a 2 M-leu-
kocyte elastase complex. This is further 
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Succ-Ala- Bz-Arg-pNa MeO-succ-Ala Succ-Phe-pNa A!a41a-^a Ala-Pro-Val-pNa 
F I G U R E 1. Hydrolysis of different peptide nitroanilides by normal plasma 
and plasma from septic shock patients (pool of six). 
"JU»3Hy(»-ol*M a c t i v i t y — 
(trt W l l t i ; 
Uucocytk tlutte « c t w i t v 
( r t w l U ) 
F I G U R E 2. Top: separation of plasma proteins from 
a septic shock patient on Sephacryl 5300. Bottom: cal­
ibration of Sephacryl 5300 with normal human plasma 
to which purified human leukocyte elastase was added. 
supported by another experiment, where 
isolated purif ied leukocyte elastase was 
added to normal plasma and fractionated 
on the same Sephacryl column: the artifi­
cial a 2M-elastase complexes eluted at the 
same place (Fig. 2, bottom) and showed an 
identical inhibit ion pattern. Peak I activity 
on the other hand is clearly unrelated to 
leukocyte elastase; it is a metalloenzyme, 
very highly specific for Succ-Ala 2-p-NA, and 
has a molecular weight which is so large 
as to suggest aggregates or association w i t h 
small particles. Similar metal-dependent 
peptide hydrolase activities have been de­
scribed previously in patients w i t h liver 
disease. 9 1 0 
Septicemia and septic shock is appar­
ently associated w i t h a raise in serum leu­
kocyte elastase levels, shown here as a 2 M 
complexes and i n agreement w i t h the oc­
curence of α Γ Α Τ complexes demonstrable 
by immunological means. 1 ' 2 1 2 In addition, 
there occurs a massive increase of a me­
talloenzyme hydrolyzing Succ-Ala 3-p-NA. 
This latter activity may reflect an involve­
ment of the liver—a general feature of en-
dotoxemia and septic shock. 1 1 
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TABLE 1. Inhibition of partially purified peptide hydrolases from plasma of spetic shock patients 
Substrate 
Peak I: Peak II: 
Succ-Ala- MeO-succ-Ala-
Ala-Ala- Ala-Pro-Val-
Inhibitors p N A p N A 
1,10 Phenanthrolin 1 m M 96% 2% 
Phenylmethyl-sulfonyl fluorid 1 m M 7% 91% 
Eglin 10 μ^ιηΐ 1% 96% 
Bowman-Birk soybean inhibitor 10 μ^παΐ 0% 44% 
Bowman-Birk soybean inhibitor 50 μ^ιηΐ 14% 75% 
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